Blog

Cancer

Dacogen (Decitabine) as a Treatment for MDS

Patient consulting with doctor about MDS and Dacogen

Decitabine is a chemotherapy (anticancer) drug available  under the brand name “Dacogen.” This anticancer drug is typically prescribed for adult patients suffering from myelodysplastic syndromes (MDS). Each year, around 10,000 people are diagnosed with myelodysplastic syndromes (MDS) in the United States. Due to the small number of individuals diagnosed with MDS, the condition is categorized as rare. As a result, Dacogen was granted the status of an orphan drug in 2006 by the FDA, which means it is a medication specifically designed to treat rare diseases.

Vorbește cu un specialist

Despre asistența pentru coplată
(877) 778-0318

This anticancer medication belongs to the DNA methylation inhibitor drug class. Dacogen is available as a sterile powder for reconstitution and injection and is only given under the supervision of a qualified healthcare professional.

What Is Dacogen Used To Treat?

The FDA has approved Dacogen as a first-line treatment in adult patients with MDS. MDS is a group of blood disorders that occur when the bone marrow (which is responsible for producing blood cells) does not function properly. In MDS patients, the bone marrow produces abnormal blood cells that do not mature properly and do not function normally. 

Subsequently, these abnormal blood cells occupy the bone marrow and replace healthy blood cells leading to low blood counts and an increased risk of infections, abnormal bleeding, and other complications. Although the exact cause of MDS is not fully understood, it is believed to occur as a result of changes or mutations in the DNA of the bone marrow cells. These mutations can lead to the abnormal growth and development of blood cells. 

By restoring normal cell function, Dacogen can help to improve blood counts and reduce the need for blood transfusions in patients with MDS.  

How Does Dacogen Work?

The active drug in Dacogen, decitabine, is a natural analog of cytidine deoxynucleoside, which is a component of the DNA structure. After Dacogen administration, this prodrug becomes active and exerts its antineoplastic (anti-tumor) effects by incorporating itself into the DNA structure. Dacogen interferes with the DNA methylation process by inhibiting the activity of an enzyme called DNA methyltransferases (DNMTs), which are essential for cancer cell development and progression. 

By blocking the activity of this enzyme, Dacogen promotes the production of normal blood cells by reactivating certain genes important for their development. This reactivation can help boost the production of normal blood cells in the bone marrow, leading to improved blood counts and a reduced need for blood transfusions.

In addition to its effects on DNA methylation, Dacogen can also induce apoptosis, or programmed cell death, in cancer cells. This may contribute to its anti-tumor effects and its ability to slow the progression of myelodysplastic syndromes (MDS).

How Long Does It Take To Work?

The time it takes for Dacogen to work can vary from person to person and may depend on several factors, including the individual’s age, overall health, the severity of their myelodysplastic syndrome (MDS), and other medical conditions they may have.

In general, it may take several weeks or even months for Dacogen to improve blood counts and other symptoms of MDS significantly. It’s important to note that Dacogen is not a cure for MDS, but rather a treatment option that can help to manage the disease and improve quality of life.

Forma de dozare și concentrația

Dacogen is usually supplied in single-dose vials containing 50 mg of decitabine as a lyophilized powder. The powder is reconstituted with 10 ml of sterile water before infusion. Each milliliter contains 5 mg of decitabine. 

Consultați un specialist în chimioterapie

Obțineți asistență pentru tratamentul chimioterapiei
Consultați un specialist în imunoglobulină (IVIG)

Dosing Information

Blood sample for Myelodysplastic syndrome test

Dacogen is given to patients in either a 3-day or 5-day regimen.

  • In the 3-day regimen, patients receive Dacogen through continuous intravenous infusion dosed at  15 mg/m2 dose over 3 hours, repeated every 8 hours for 3 days. After the 3-day period, patients rest for 6 weeks before starting the next cycle. 
  • On the other hand, in the 5-day regimen, patients receive Dacogen through continuous intravenous infusion at a 20 mg/m2 dose over 1 hour, repeated daily for 5 days. After the 5-day period, patients rest for 4 weeks before starting the next cycle. 

Overdose 

An overdose of Dacogen may increase myelosuppression, including prolonged thrombocytopenia and neutropenia.

How Is Dacogen Given?

Dacogen is administered by injection into a vein over a period of several hours, typically for 5 consecutive days, followed by a period of rest. It is only available by prescription and should only be used under the supervision of a qualified healthcare professional.

Is Dacogen a Form of Chemotherapy?

Yes, Dacogen is a form of chimioterapie that stops or slows the growth of cancer cells and helps to improve symptoms and increase survival rates for patients with MDS.

As a form of chemotherapy, Dacogen is typically administered via injection into the bloodstream, either in a hospital or clinic setting. However, it is usually used at lower doses than traditional chemotherapy drugs, which may help reduce some side effects commonly associated with chemotherapy, such as nausea, hair loss, and fatigue.

Possible Side Effects

Dacogen also has some common and severe side effects, like other medications. The most common side effects are:

  • Febră
  • Injection site reactions
  • Anemia (low RBC count)
  • Thrombocytopenia (low blood platelets count)
  • Neutropenia (low white blood cell count)

Get Financial Assistance for Dacogen

(877) 778-0318

Precauții

If you have certain medical conditions, Dacogen may not be suitable for you. Therefore, it is recommended to consult your healthcare provider in the following cases before taking Dacogen: 

  • If you are gravidă sau intend to become pregnant, avoid receiving Dacogen infusion as it may cause fetal-born toxicity and harm the baby. 
  • If you are alăptarea sau planificarea alăptării, avoid receiving Dacogen during breastfeeding, or if you are already taking Dacogen, then do not breastfeed the child for at least 1 week after the last dose. 
  • If you are a fertile man or woman, use effective contraceptives to avoid pregnancy while receiving treatment with Dacogen. This medication can cause congenital disabilities and may harm the fetus. Fertile women should use birth control for at least 6 months after the last dose, and men for 3 months after the last dose. 
  • If you have an allergy to any component of Dacogen, do not take this medication.
  • If you have liver or kidney disease, consult your doctor.
  • If you are taking multivitamins, herbal supplements, or over-the-counter medicines, talk to your doctor before taking Dacogen. 

Cost 

The cost of Dacogen intravenous powder of 50 mg is around $1,901. The cost of this medication can vary and may depend on the pharmacy you visit. Contactaţi-ne if you would like help finding financial assistance. 

REFERINȚE:

  1. US Food and Drug Administration (FDA). Dacogen Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021790s021lbl.pdf
  2. Nieto, M. J., Demolis, P., Béhanzin, E., Moreau, A., Hudson, I., Flores, B. R., Stemplewski, H., Salmonson, T., Gisselbrecht, C., Bowen, D. G., & Pignatti, F. (2016). The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Oncologist, 21(6), 692–700. https://doi.org/10.1634/theoncologist.2015-0298
  3. Jabbour, E., Issa, J. P. J., Garcia-Manero, G., & Kantarjian, H. M. (2008). Evolution of decitabine development. Cancer, 112(11), 2341–2351. https://doi.org/10.1002/cncr.23463
  4. Aronson, J. K. (2015). Meyler’s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Elsevier.
Aceste informații nu înlocuiesc sfatul sau tratamentul medical. Discutați cu medicul dumneavoastră sau cu furnizorul de servicii medicale despre afecțiunea dumneavoastră medicală înainte de a începe orice tratament nou. AmeriPharma® Specialty Care nu își asumă nicio răspundere pentru informațiile furnizate sau pentru orice diagnostic sau tratament efectuat ca urmare a acestuia și nici nu este responsabil pentru fiabilitatea conținutului. AmeriPharma® Specialty Care nu operează toate site-urile web/organizațiile enumerate aici și nici nu este responsabil pentru disponibilitatea sau fiabilitatea conținutului acestora. Aceste listări nu implică și nu constituie o aprobare, sponsorizare sau recomandare din partea AmeriPharma® Specialty Care. Această pagină web poate conține referințe la medicamente eliberate pe bază de rețetă, care sunt mărci comerciale sau mărci comerciale înregistrate ale producătorilor farmaceutici care nu sunt afiliați cu AmeriPharma® Specialty Care.
REVIZUIT MEDICAL DE Dr. Christine Leduc, doctor în farmacii

Dr. Christine Leduc, doctor în farmacii, s-a născut și a crescut în Irvine, California. A urmat facultatea la Universitatea Midwestern, unde a absolvit cu distincție cum laude. Cea mai satisfăcătoare parte a slujbei sale este sugerarea schimbărilor în stilul de viață, educarea pacienților cu privire la modul în care funcționează medicamentele lor și îndrumarea viitorilor farmaciști. Domeniile sale de expertiză sunt serviciul clienți și cunoașterea medicamentelor de specialitate. Având experiență în domeniul serviciilor în trecut, a dobândit abilitățile de serviciu clienți necesare pentru a înțelege nevoile pacienților săi. Dr. Leduc învață în prezent studenți de la Universitatea Marshall B. Ketchum, Universitatea din Kansas și Universitatea Midwestern. În timpul liber, îi place să călătorească, să coacă și să grădinărească. Vezi biografia autorului

Contactaţi-ne

Folosiți formularul conform HIPAA de mai jos pentru a solicita o reînnoire a rețetei dumneavoastră. Dacă aveți întrebări despre medicamentul dumneavoastră sau despre cum să îl administrați, vă rugăm să vizitați pagina Contactați-ne sau să ne sunați la (877) 778-0318.

HIPAA Compliant

Prin trimitere, sunteți de acord cu AmeriPharma Termeni de utilizare, Politica de confidențialitateși Notificare privind practicile de confidențialitate

ro_RORomanian